【www.zhangdahai.com--企业文化建设】
【摘要】 目的 观察重组人血管内皮抑制素(恩度)治疗恶性胸腔积液的近期疗效，评价恩度局部应用的疗效、安全性及耐受性。方法 将病例随机分为两组：A组(治疗组)18例，B组(对照组)14例。治疗组胸腔注入恩度30 mg+0.9%氯化钠注射液40 ml；对照组胸腔注入顺铂40 mg+0.9%氯化钠注射液60 ml，每周2次，共2~4次。结果 A组(治疗组)中CR 5例，PR 9例,ND 4例，有效率77.8%。B组(对照组)CR2例，PR5例，ND7例，有效率50%。A组副反应较轻。
结论 顺铂和恩度胸腔灌注治疗恶性胸腔积液，均能有效控制恶性胸腔积液，但恩度有效率高于顺铂组，而且副反应较轻。�
【关键词】 重组人血管内皮抑制素；恶性胸腔积液；有效率；安全性
��Clinical observation of Endostar in the treatment of m alignant pleural effusion
JIA Qing�qing，SUN Chang�jiang.Department of Oncology,Affiliated Subei Hospital of Yangzhou University,Jiansu 225000,China
�h
【Abstract】 Objective To observe the clinical efficacy of recombinant human endostatin(Endostar)for control m alignant pleural effusion,evaluate the safety and tolerability of intracavitary infusion of Endostar.Methods Thirty�two m alignant tumors patients were divided into two groups.A group(therapy group,18 cases)were treated with Endostar into thoracic cavity.B group(control group,14 cases)were treated with Cisplatin,twice a week,in 2~3 rounds.Results The efficacy oftherpy group:5 cases of CR,9 cases of PR,4 cases of ND with 77.8%efficiency rate; and 50%for the B group(control group)(P
